#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	8388	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2109	392.1	0	.	n	.	0	C1450T	SNP	1450	1450	C	1683	1683	T	504	T,C	482,2	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	8388	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2109	392.1	1	SNP	n	C1184T	0	.	.	1184	1184	C	1417	1417	C	475	C	463	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	8388	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2109	392.1	0	HET	.	.	.	C1320T	.	1320	1320	C	1553	1553	C	519	C,T	404,99	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	15398	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3488	436.7	0	.	n	.	0	G1337A	SNP	1337	1337	G	1623	1623	A	475	A,G	464,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	15398	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3488	436.7	0	.	n	.	0	T1971C	SNP	1971	1971	T	2257	2257	C	465	C	449	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	15398	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3488	436.7	1	SNP	n	A2045G	0	.	.	2045	2045	A	2331	2331	A	454	A	444	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	15398	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3488	436.7	1	SNP	n	C2597T	0	.	.	2597	2597	C	2883	2883	C	463	C	448	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
blaTEM.WHO_M_pConjugative_00003	blaTEM.WHO_M_pConjugative_00003	1	0	0	14	blaTEM	861	99	100.0	blaTEM.l15.c4.ctg.1	123	3.3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Betalactam resistance
blaTEM.WHO_M_pConjugative_00003	blaTEM.WHO_M_pConjugative_00003	1	0	0	14	blaTEM	861	155	100.0	blaTEM.l15.c4.ctg.2	155	2.6	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Betalactam resistance
folP.WHO_O_01412c	folP.WHO_O_01412c	1	1	27	992	folP	855	855	100.0	folP.l15.c4.ctg.1	1548	63.8	1	SNP	p	R229S	1	.	.	685	687	AGC	1019	1021	AGC	97;97;98	A;G;C	95;93;94	folP.WHO_O_01412c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	2942	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3392	86.1	1	SNP	p	S91F	1	.	.	271	273	TTC	619	621	TTC	94;94;96	T;T;C	93;93;94	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	2942	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3392	86.1	1	SNP	p	D95G	1	.	.	283	285	GGC	631	633	GGC	93;93;95	G;G;C	92;93;95	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	2942	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3392	86.1	1	SNP	p	G95N	0	.	.	283	285	GGC	631	633	GGC	93;93;95	G;G;C	92;93;95	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	27	950	mtrR	633	633	100.0	mtrR.l6.c30.ctg.1	1308	71.8	1	SNP	p	G45D	0	.	.	133	135	GGC	457	459	GGC	116;115;114	G,T;G;C	110,1;110;107	mtrR.WHO_O_01438:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	514	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	847	60.1	0	.	n	.	0	A197.	DEL	197	197	A	493	493	A	123	A	121	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	2534	parC	2304	2304	99.83	parC.l15.c4.ctg.1	2927	85.7	0	.	p	.	0	G120R	NONSYN	358	360	GGG	653	655	AGG	97;97;96	A;G;G	89;92;92	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	2534	parC	2304	2304	99.83	parC.l15.c4.ctg.1	2927	85.7	0	.	p	.	0	I384V	NONSYN	1150	1152	ATC	1445	1447	GTC	115;115;117	G;T;C	113;108;113	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	2534	parC	2304	2304	99.83	parC.l15.c4.ctg.1	2927	85.7	1	SNP	p	D86N	0	.	.	256	258	GAC	551	553	GAC	110;108;108	G;A;C	108;106;106	parC.WHO_V_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	2534	parC	2304	2304	99.83	parC.l15.c4.ctg.1	2927	85.7	1	SNP	p	R87I	0	.	.	259	261	CGT	554	556	CGT	109;108;107	C;G;T	107;106;103	parC.WHO_V_00204c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	2534	parC	2304	2304	99.83	parC.l15.c4.ctg.1	2927	85.7	1	SNP	p	S87R	1	.	.	259	261	CGT	554	556	CGT	109;108;107	C;G;T	107;106;103	parC.WHO_V_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	2534	parC	2304	2304	99.83	parC.l15.c4.ctg.1	2927	85.7	1	SNP	p	R87W	0	.	.	259	261	CGT	554	556	CGT	109;108;107	C;G;T	107;106;103	parC.WHO_V_00204c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	2534	parC	2304	2304	99.83	parC.l15.c4.ctg.1	2927	85.7	1	SNP	p	S88P	0	.	.	262	264	TCC	557	559	TCC	108;113;115	T;C;C	105;109;110	parC.WHO_V_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	2200	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2425	89.5	0	.	p	.	0	R340C	NONSYN	1018	1020	CGC	1239	1241	TGC	105;102;102	T;G;C	102;99;101	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	2200	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2425	89.5	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1449	1451	GGC	105;104;102	G;G;C	103;100;97	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.12.001	penA.12.001	1	1	27	2388	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2521	93.8	1	SNP	p	A311V	0	.	.	931	933	GCA	1347	1349	GCA	129;130;130	G;C;A	122;125;127	penA.12.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	2388	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2521	93.8	1	SNP	p	I312M	0	.	.	934	936	ATC	1350	1352	ATC	133;133;131	A;T;C	128;127;126	penA.12.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	2388	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2521	93.8	1	SNP	p	V316T	0	.	.	946	948	GTG	1362	1364	GTG	128;128;129	G;T;G	124;122;126	penA.12.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	2388	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2521	93.8	1	SNP	p	V316P	0	.	.	946	948	GTG	1362	1364	GTG	128;128;129	G;T;G	124;122;126	penA.12.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	2388	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2521	93.8	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1866	1868	ACC	122;121;122	A;C;C	113;116;116	penA.12.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	2388	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2521	93.8	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1920	1922	GCG	135;132;136	G,C;C,G;G	125,2;111,2;128	penA.12.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	2388	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2521	93.8	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1920	1922	GCG	135;132;136	G,C;C,G;G	125,2;111,2;128	penA.12.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	2388	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2521	93.8	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2043	2045	GGC	94;94;93	G;G;C	91;91;89	penA.12.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	2388	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2521	93.8	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2052	2054	GGC	95;94;92	G;G;C,G	92;92;90,1	penA.12.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	2388	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2521	93.8	1	SNP	p	P552S	1	.	.	1654	1656	TCG	2070	2072	TCG	81;84;82	T,G;C;G,C	59,6;76;74,1	penA.12.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	3540	ponA	2397	2397	100.0	ponA.l6.c4.ctg.1	3102	113.2	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1596	1598	CCG	111;111;108	C;C;G	102;105;101	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	1340	porA	1146	1146	99.56	porA.l15.c4.ctg.1	1861	71.0	0	.	p	.	0	M83fs	FSHIFT	247	247	A	554	554	C	103	C	98	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	1550	porB1b	1047	1047	99.33	porB1b.l6.c4.ctg.1	1518	101.2	0	.	p	.	0	N38E	NONSYN	112	114	AAT	386	388	GAA	118;116;114	G;A;A	114;112;110	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	1550	porB1b	1047	1047	99.33	porB1b.l6.c4.ctg.1	1518	101.2	0	.	p	.	0	N134D	NONSYN	400	402	AAT	674	676	GAT	110;107;107	G;A;T	108;104;104	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	1550	porB1b	1047	1047	99.33	porB1b.l6.c4.ctg.1	1518	101.2	0	.	p	.	0	P175S	NONSYN	523	525	CCA	797	799	TCA	118;120;119	T;C;A	114;116;116	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	1550	porB1b	1047	1047	99.33	porB1b.l6.c4.ctg.1	1518	101.2	0	.	p	.	0	A218V	NONSYN	652	654	GCC	926	928	GTC	132;129;130	G;T;C	123;119;123	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	1550	porB1b	1047	1047	99.33	porB1b.l6.c4.ctg.1	1518	101.2	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1256	1258	GCA	141;141;141	G;C;A	135;135;135	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	1550	porB1b	1047	1047	99.33	porB1b.l6.c4.ctg.1	1518	101.2	1	SNP	p	G120K	1	.	.	358	360	AAG	632	634	AAG	111;111;110	A;A;G	109;109;109	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	1550	porB1b	1047	1047	99.33	porB1b.l6.c4.ctg.1	1518	101.2	1	SNP	p	D121N	0	.	.	361	363	GAC	635	637	GAC	110;111;111	G;A;C	109;109;110	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	1550	porB1b	1047	1047	99.33	porB1b.l6.c4.ctg.1	1518	101.2	1	SNP	p	A121D	1	.	.	361	363	GAC	635	637	GAC	110;111;111	G;A;C	109;109;110	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	5950	rpoB	4179	4179	100.0	rpoB.l6.c17.ctg.1	4827	122.3	1	SNP	p	H553N	1	.	.	1657	1659	AAT	1975	1977	AAT	134;133;132	A,C;A;T	132,1;132;130	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	738	rpsJ	312	312	100.0	rpsJ.l15.c17.ctg.1	1040	70.5	1	SNP	p	V57M	1	.	.	169	171	ATG	543	545	ATG	123;122;122	A;T;G	119;117;118	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
